Frag' FlorenceEvidenz. Klar. Anwendbar.
Uhr 7/8Sources Journal Tree
Easy Demo

Lokaler Crossref-Datenbestand · journal-article

JJCO Best Reviewer Award

Japanese Journal of Clinical Oncology · 2020

Vollständiger Abstract

Worum geht es in dieser Arbeit?

OBJECTIVES: Spread through air spaces (STAS) is a poor prognostic pathological feature recently included as a histological factor in the ninth edition of the TNM (tumor, node, and metastasis) classification. However, its clinical significance in lung adenocarcinoma with epidermal growth factor receptor (EGFR) gene mutations remains unclear. Here, we aimed to evaluate the clinical significance of STAS according to EGFR mutation status. METHODS: We retrospectively reviewed 347 patients with completely resected pathological stage 0-IIIB lung adenocarcinoma who were evaluated for both STAS and EGFR mutations between 2015 and 2022. We investigated the association between clinicopathological features and STAS and analyzed its prognostic relevance based on EGFR mutation status. RESULTS: STAS and EGFR mutations were present in 85 (24.5%) and 178 (51.3%) patients, respectively. In patients with EGFR-mutated lung adenocarcinoma, STAS was significantly more prevalent in those with exon 19 deletions than those with the L858R mutation (P = .012). STAS was significantly markedly associated with poorer recurrence-free and overall survival in patients both with (P < .001 and P < .001, respectively) and without (P = .003 and P = .023, respectively) EGFR mutations. Multivariable analysis revealed that STAS was an independent prognostic factor for recurrence-free and overall survival in patients with EGFR mutations (P < .001 and P = .020, respectively). However, STAS was not an independent predictor in patients without EGFR mutations. CONCLUSIONS: STAS is a key pathological feature of lung adenocarcinoma and holds considerable clinical relevance, particularly in EGFR-mutated lung adenocarcinoma.

Abstract: PubMed · Datensatz

Bibliografischer Nachweis

Publikationsdaten

Autor:innen
Nicht angegeben
Quelle
Japanese Journal of Clinical Oncology
Publikation
2020-01-01
Band / Ausgabe
Nicht angegeben
Seiten
Nicht angegeben
ISSN / ISBN
1465-3621
Zitationen
1 laut Crossref
Referenzen
0 hinterlegt

Zitieren

Zitierfähiger Nachweis

(2020). JJCO Best Reviewer Award. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyag129
RIS BibTeX CSL-JSON

Kontext

Themen, Förderung und Nutzung

Lizenzhinweise: Lizenz 1